NCT02166255View on ClinicalTrials.gov

APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Recurrent MelanomaRecurrent Pancreatic CancerRecurrent Renal Cell CancerStage III Pancreatic CancerStage III Renal Cell CancerStage IIIA MelanomaStage IIIB MelanomaStage IIIC MelanomaStage IV MelanomaStage IV Pancreatic CancerStage IV Renal Cell CancerUnspecified Adult Solid Tumor, Protocol Specific
Interventions
BIOLOGICAL

siRNA-transfected peripheral blood mononuclear cells APN401

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

27157

Comprehensive Cancer Center of Wake Forest University, Winston-Salem

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Wake Forest University Health Sciences

OTHER

NCT02166255 - APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery | Biotech Hunter | Biotech Hunter